Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.38 |
| ▸ | BHMT | Q93088 | 1/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5053902 | 1.00 | PDCD1LG2 (0.48) | PDCD1LG2CD274MMEDPP4DPP8 | |
| SCHEMBL8526326 | 1.00 | PDCD1LG2 (0.48) | PDCD1LG2CD274MMEDPP4DPP8 | |
| SCHEMBL30462197 | 0.94 | PDCD1LG2 (0.44) | PDCD1LG2CD274MMEDPP4DPP8 | |
| SCHEMBL29599569 | 0.89 | ENPEP (0.50) | ENPEP | |
| SCHEMBL29867109 | 0.89 | PDCD1LG2 (0.50) | PDCD1LG2CD274MMEVSIR | |
| SCHEMBL31319509 | 0.88 | OPRM1 (0.46) | PDCD1LG2CD274MME | |
| SCHEMBL8528144 | 0.88 | CD274 (0.57) | PDCD1LG2CD274MMEDPP4DPP8 | |
| SCHEMBL29572257 | 0.88 | CD274 (0.57) | PDCD1LG2CD274MMEDPP4DPP8 | |
| SCHEMBL29572216 | 0.88 | CD274 (0.57) | PDCD1LG2CD274MMEDPP4DPP8 | |
| SCHEMBL5998197 | 0.88 | CD274 (0.57) | PDCD1LG2CD274MMEDPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240241107-A1 | SERUM METABOLOMICS RELATED TO CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-18 | — | — | US | disclosed |
| CN-117915926-A | Serometabonomics associated with Chimeric Antigen Receptor (CAR) T cell therapy | 得克萨斯州大学系统董事会 | 2024-04-19 | — | — | CN | disclosed |
| EP-4333860-A1 | SERUM METABOLOMICS RELATED TO CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY | Board of Regents, The University of Texas System (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230358751-A1 | METHODS FOR THE DETECTION AND TREATMENT OF PROSTATE CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2022236131-A1 | SERUM METABOLOMICS RELATED TO CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-0885899-A1 | Method for obtaining peptide fragments by use of fluorinated organic acids | SEIKO INSTRUMENTS INC. (JP) | 1998-12-23 | — | — | EP | disclosed |